Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: A cross-sectional study

Urology

Volumn 77, Issue 1, 2011, Pages 154-159

  Hwang, Eu Chang ^a   Choi, Hyang Sik ^a   Jung, Seung Il ^a   Kwon, Dong Deuk ^a   Park, Kwangsung ^a   Ryu, Soo Bang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; BLADDER EXAMINATION; CANCER DIAGNOSIS; CANCER SCREENING; CROSS-SECTIONAL STUDY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MATRIX PROTEIN 22 BLADDERCHECK TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; CARCINOMA, TRANSITIONAL CELL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 78650918257     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.04.059     Document Type: Article

References (24)

1. Y. Lotan, and C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 61 2003 109 118
2. P.I. Karakiewicz, S. Benayoun, and C. Zippe Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder BJU Int 97 2006 997 1001
3. B.W. van Rhijn, H.G. van der Poel, and T.H. van der Kwast Urine markers for bladder cancer surveillance: a systematic review Eur Urol 47 2005 736 748
4. D. Zaak, M. Kriegmair, and H. Stepp Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies Urology 57 2001 690 694
5. S. Schneeweiss, M. Kriegmair, and H. Stepp Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent J Urol 161 1999 1116 1119
6. V. Menendez, X. Filella, and J.A. Alcover Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder Anticancer Res 20 2000 1169 1172
7. Y. Lotan, S.F. Shariat NMP22 Study Group Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection BJU Int 101 2008 1362 1367
8. S. Zeitlin, A. Parent, and S. Silverstein Pre-mRNA splicing and the nuclear matrix Mol Cell Biol 7 1987 111 120
9. G.A. Carpinito, W.M. Stadler, and J.V. Briggman Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract J Urol 156 1996 1280 1285
10. S.K. Keesee, J.V. Briggman, and G. Thill Utilization of nuclear matrix proteins for cancer diagnosis Crit Rev Eukaryot Gene Expr 6 1996 189 214
11. T.E. Miller, L.A. Beausang, and L.F. Winchell Detection of nuclear matrix proteins in serum from cancer patients Cancer Res 52 1992 422 427
12. V.B. Lokeshwar, T. Habuchi, and H.B. Grossman Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers Urology 66 2005 35 63 (Pubitemid 43049608)
13. P.M. Moonen, L.A. Kiemeney, and J.A. Witjes Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer Eur Urol 48 2005 951 956 [Discussion:956]
14. A. Kumar, R. Kumar, and N.P. Gupta Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer Jpn J Clin Oncol 36 2006 172 175
15. K.M. Tomera NMP22 BladderChek test: point-of-care technology with life- and money-saving potential Expert Rev Mol Diagn 4 2004 783 794
16. H.B. Grossman, M. Soloway, and E. Messing Surveillance for recurrent bladder cancer using a point-of-care proteomic assay JAMA 295 2006 299 305
17. H. Boman, H. Hedelin, and S. Holmang Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence J Urol 167 2002 80 83
18. J.S. Kim, H.M. Lee, and K.H. Lee The significance of urinary nuclear matrix protein (NMP) as a marker for transitional cell carcinoma of the bladder Korean J Urol 38 1997 259 262
19. H. Kim, S.G. Chang, and J.I. Kim Significance of urinary NMP22 in patients with bladder tumor as a diagnostic test Korean J Urol 39 1998 450 453
20. J.O. Park, D.G. Moon, and J. Cheon Urinary NMP (nuclear matrix protein) In Screening and Post-treatment Follow-up of Bladder Cancer Korean J Urol 40 1999 551 556
21. D.H. Kwon, and S.J. Hong The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: A Comparative Study Korean J Urol 44 2003 721 726
22. S. Hautmann, M. Toma, and M.F. Lorenzo Gomez Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison Eur Urol 46 2004 466 471
23. X.Y. Pu, Z.P. Wang, and Y.R. Chen The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine J Cancer Res Clin Oncol 134 2008 659 665
24. I. Soyuer, M. Sofikerim, and F. Tokat Which urine marker test provides more diagnostic value in conjunction with standard cytology-ImmunoCyt/uCyt+ or cytokeratin 20 expression Diagn Pathologe 4 2009 20 25